A Dose of Economics
Health economics podcast hosted by Grace Hampson, a Director at the Office of Health Economics (OHE). Each episode features conversations with leading health economists, researchers, and policy experts on topics like HTA, NICE thresholds, cost-effectiveness, AMR, AI in health, drug shortages, and the future of healthcare decision-making. New episodes every Tuesday.
Episodes
What is your health worth? PROMs, EQ-5D & economic evaluation
How do we actually measure health? And in health economics, what is the difference between measuring health and assigning a value to it? Grace Hampson is joined by David Mott, Associate Director at OHE, as well as Hannah Hussain, an Economist at OHE, both part of OHE’s Measuring and Valuing Outcomes team. They’ll unpack how health economists measure and value health, and why getting this right ma
AI and the future of health economics
AI is already reshaping how healthcare policy works. The question is not whether AI will also transform health economics – but how quickly, and whether we are ready for the opportunities and challenges it could bring. There is incredible potential here, but also real questions about rigour, accountability, and what AI means for people working in this space. Grace Hampson is joined by Tim Reason,
Should HTA look beyond the healthcare system?
When healthcare systems assess the value of a new medicine, should they only count the impact on the patient's health and the healthcare budget? The case for a broader, societal perspective in health technology assessment has been building for years, but so have the arguments against it. Grace Hampson is joined by Chris Skedgel, a Director at OHE, to dig into one of health economics' m
Can joint clinical assessment speed up access to medicines?
The Joint Clinical Assessment (JCA) is a milestone in European health policy, promising a single shared evaluation of the efficacy and safety of new medicines across EU member states. Theoretically, this should mean consistency for innovators and faster access to medicines for patients. But one year on, how is JCA working in practice, and what needs to happen next? Grace Hampson is joined by Pa
When antibiotics stop working: the hidden crisis in plain sight
Around 5 million deaths per year are linked to antimicrobial resistance (AMR) and this number is growing, with AMR-related deaths predicted to surpass deaths from cancer by 2050. And yet, the global pipeline of new antibiotics is critically underdeveloped. So how do we address the problem? Grace Hampson is joined by Lotte Steuten, Deputy Chief Executive of the Office of Health Economics and David
Most Favored Nation pricing: what it means for policy, patients and pharma
US pharmaceutical prices are the highest in the world -- President Trump's Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice? And what are the global ripple effects on drug innovation and R&D? Grace Hampson is joined by Neil Grubert and Amanda Cole to talk about the biggest developments in U.S drug pricing policy – and what it means for
Welcome to A Dose of Economics
When demand for healthcare is growing but budgets are finite, the "how" and "why" of decision-making matters. In this first episode, host Grace Hampson, a Director at the Office of Health Economics (OHE), introduces the podcast, and sets out what you can expect this season. One question will run through every conversation: what can health economics bring to the most pressing pr
